Loading
A phase 3 trial of Trastuzumab deruxtecan, Rilvegostomig, Pembrolizumab in endometrial cancer, run by AstraZeneca, now recruiting.
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer is a phase 3 interventional study registered as NCT06989112 by AstraZeneca, with 600 participants planned, started 2025-03-27 and due to reach its primary completion in 2029-01-19. Interventions recorded: Trastuzumab deruxtecan, Rilvegostomig, Pembrolizumab, Carboplatin, Paclitaxel. Conditions listed: Endometrial Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Rilvegostomig, T-cell exhaustion and CAR-T persistence, Paclitaxel / nab-paclitaxel, AstraZeneca.
Shares Docetaxel, Topoisomerase-I inhibitors (and ADC payloads), Endometrial cancer, Paclitaxel / nab-paclitaxel.
Shares Rilvegostomig, T-cell exhaustion and CAR-T persistence, Trastuzumab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads).
Shares Rilvegostomig, T-cell exhaustion and CAR-T persistence, Trastuzumab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads).
Shares Rilvegostomig, T-cell exhaustion and CAR-T persistence, Topoisomerase-I inhibitors (and ADC payloads), AstraZeneca.
Shares Rilvegostomig, T-cell exhaustion and CAR-T persistence, AstraZeneca, Carboplatin.
Shares Rilvegostomig, T-cell exhaustion and CAR-T persistence, Topoisomerase-I inhibitors (and ADC payloads), Endometrial cancer.
Shares Advanced or recurrent endometrial cancer, Docetaxel, Endometrial cancer, Carboplatin.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/